Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

IMRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Immuneering CorporationNASDAQ: IMRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 44.01M shares rose 23.9% year over year, behind the +29.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +23.9% toward the trailing-twelve-month pace of +29.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
44.01M+0.0% QoQ
Last fiscal yearDec 2025
44.01M+46.8% YoY
LTMMar 2026
40.92M+29.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.9%——
1 year+46.8%——
3-year CAGR+18.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
44.01M USD
Year-over-year change
+46.8%
4-year CAGR
+13.7%

Weighted Avg Shares (Diluted) vs competitors

How IMRX compares with its peers on the latest reported figures

  • IMRX's LTM Mar 2026 weighted avg shares (diluted) of 40.92M shares is the 8th highest of the 11 companies compared; the peer median is 63.58M shares.
  • Its year-over-year change of +29.8% is the 5th highest of 11, against a peer median of +5.7%.
  • Over three fiscal years its annual growth of +18.6% compares with a peer median of +15.1%.
IMRX Competitors Peer median
Weighted Avg Shares (Diluted) for IMRX and competitors
Company Period LTM YoY 3-year CAGR
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.0%+15.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +3.6%+9.8%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding IMRX) 63.58M+5.7%+15.1%

Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.08M316.95K000
Cost of Revenue1.15M158.12K00698.89K
Gross Profit926.89K158.83K00(698.89K)
Gross Margin44.6%50.1%———
Research & Development26.54M36.27M41.62M47.96M42.05M
Selling, General & Admin8.27M15.61M16.76M16.08M17.3M
Operating Expenses34.81M51.9M58.41M64.07M58.68M
Depreciation & Amortization159.07K277.25K352.08K385.07K698.89K
EBITDA(33.68M)(51.47M)(58.06M)(63.69M)(55.33M)
EBITDA Margin-1619.5%-16238.4%———
Operating Income(33.89M)(51.74M)(58.41M)(64.07M)(59.38M)
Operating Margin-1629.2%-16325.8%———
Interest Income169.9K1.01M3.61M2.59M3.04M
Interest Expense00000
Other Income / Expenses42.83K1.23M4.94M3.03M3.35M
Income Before Tax(33.84M)(50.51M)(53.47M)(61.04M)(56.02M)
Pre-Tax Margin-1627.1%-15937.4%———
Income Tax Expense(307.49K)0000
Net Income(33.54M)(50.51M)(53.47M)(61.04M)(56.02M)
Net Margin-1612.3%-15937.3%———
EPS (Basic)(1.27)(1.87)(1.88)(2.04)(1.27)
EPS (Diluted)(1.27)(1.87)(1.88)(2.04)(1.27)
Weighted Avg Shares26.32M26.39M28.42M29.98M44.01M
Weighted Avg Shares (Diluted)26.32M26.39M28.42M29.98M44.01M

Immuneering Corporation

NASDAQ:IMRX

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.